Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: XH-S003 Capsules · Paroxysmal Nocturnal Hemoglobinuria (PNH) Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Phase 2 NCT06978699
  2. Notable: Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation Phase changed: Phase 2/3 → Phase 3 Mayo ClinicPhase 3 NCT07487818
  3. Notable: IMPACT-MACS · Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Phase changed: Not applicable → Phase 4 University of Texas Southwestern Medical CenterPhase 4 NCT07361874
  4. Notable: Multimodal AI-based Region-specific Ablation Planning for Hepatocellular Carcinoma: Model Development, External Validation, and a Multicenter Randomized Trial Phase changed: Not specified → Not applicable Chinese PLA General HospitalNot applicable NCT06798194
  5. Notable: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Recruitment opened Boehringer IngelheimPhase 3 NCT07855900
  6. Notable: Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules · Early-Onset Parkinson's Disease Recruitment opened Hangzhou PhecdaMed Co., Ltd.Phase 3 NCT07741045
  7. Notable: SYNCHRONIZE®-HERA · Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Recruitment opened Boehringer IngelheimPhase 3 NCT07850050
  8. Notable: GC3114B in Adults Aged 65 Years or Older Recruitment opened GC Biopharma CorpPhase 2/3 NCT07883928
  9. Notable: IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis · Chronic Hepatitis B Recruitment opened Beijing Continent Pharmaceutical Co, Ltd.Phase 3 NCT07412236
  10. Notable: ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs Recruitment opened Enliven TherapeuticsPhase 3 NCT07905183
  11. Notable: Continuation Study of Tilrekimig · Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time Recruitment opened PfizerPhase 3 NCT07839884
  12. Notable: Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors Recruitment opened Regeneron PharmaceuticalsPhase 1/2 NCT07863024
  13. Notable: RT023 · Advanced Solid Tumors Recruitment opened Shanghai Ruotuo Biosciences Co., Ltd.Phase 1/2 NCT07797426
  14. Notable: MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) Recruitment opened Imagion Biosystems, Inc.Phase 1/2 NCT07885683
  15. Notable: GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) Recruitment opened Eddingpharm (Zhuhai) Co., Ltd.Phase 1/2 NCT07738341
  16. Notable: Modzatinib (ATI-2138) · Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies Recruitment opened Aclaris Therapeutics, Inc.Phase 2 NCT07935590
  17. Notable: BMS-986511 · Major Depressive Disorder Recruitment opened Bristol-Myers SquibbPhase 2 NCT07772531
  18. Notable: SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer Recruitment opened Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2 NCT07863167
  19. Notable: LY4247147 · Obesity or Overweight Who Are Otherwise Healthy Recruitment opened Eli Lilly and CompanyPhase 1 NCT07915245
  20. Notable: HH-1270 in Healthy Chinese Subjects Recruitment opened Huahui HealthPhase 1 NCT07876440
  21. Notable: LY4560736 in Healthy Participants and · Alzheimer's Disease (AD) Recruitment opened Eli Lilly and CompanyPhase 1 NCT07843459
  22. Notable: LY4167586 · Obesity or Overweight With or Without Type 2 Diabetes Recruitment opened Eli Lilly and CompanyPhase 1 NCT07881887
  23. Notable: LY4515100 in Healthy Male Participants Recruitment opened Eli Lilly and CompanyPhase 1 NCT07867327
  24. Notable: LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and · Inflammation (High C-Reactive Protein) Recruitment opened Eli Lilly and CompanyPhase 1 NCT07867340
  25. Notable: Dietary Supplement to Alleviate Dry Mouth Recruitment opened Lacer S.A.Not applicable NCT07847840